ATE529109T1 - Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe - Google Patents
Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffeInfo
- Publication number
- ATE529109T1 ATE529109T1 AT98964709T AT98964709T ATE529109T1 AT E529109 T1 ATE529109 T1 AT E529109T1 AT 98964709 T AT98964709 T AT 98964709T AT 98964709 T AT98964709 T AT 98964709T AT E529109 T1 ATE529109 T1 AT E529109T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibition
- kinase activity
- substituted heterocyclic
- heterocyclic ureas
- ureas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/42—Benzene-sulfonamido pyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99575097A | 1997-12-22 | 1997-12-22 | |
PCT/US1998/026080 WO1999032111A1 (en) | 1997-12-22 | 1998-12-22 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE529109T1 true ATE529109T1 (de) | 2011-11-15 |
Family
ID=25542167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98964709T ATE529109T1 (de) | 1997-12-22 | 1998-12-22 | Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1041982B1 (de) |
JP (1) | JP4403482B2 (de) |
AT (1) | ATE529109T1 (de) |
AU (1) | AU739642B2 (de) |
CA (1) | CA2315720A1 (de) |
DE (1) | DE1041982T1 (de) |
ES (1) | ES2154253T3 (de) |
IL (3) | IL136738A0 (de) |
MX (1) | MXPA00006233A (de) |
WO (1) | WO1999032111A1 (de) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1019040B1 (de) * | 1997-05-23 | 2004-09-29 | Bayer Corporation | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
EP1473292A1 (de) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatische heterocyclische Verbindungen als antiinflammatorische Mittel |
JP4437270B2 (ja) * | 1997-12-22 | 2010-03-24 | バイエル コーポレイション | 置換複素環式尿素を用いたrafキナーゼの阻害 |
AU2006201959B2 (en) * | 1997-12-22 | 2008-09-04 | Bayer Healthcare Llc | Inhibition of Raf Kinase using Substituted Heterocyclic Ureas |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
SI1140840T1 (sl) * | 1999-01-13 | 2006-06-30 | Bayer Pharmaceuticals Corp | Omega-karboksiarilno substituirane difenil secnine kot inhibitorji raf kinaze |
EP1158985B1 (de) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
WO2000050425A1 (en) | 1999-02-22 | 2000-08-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
EP1163236B1 (de) * | 1999-03-12 | 2005-11-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatische heterozyklische verbindungen als antientzündungwirkstoffe |
DE60014603T2 (de) | 1999-03-12 | 2006-02-16 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
WO2001004115A2 (en) | 1999-07-09 | 2001-01-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
CN1373662A (zh) | 1999-08-12 | 2002-10-09 | 法玛西雅意大利公司 | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 |
JP4955171B2 (ja) * | 1999-11-16 | 2012-06-20 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての尿素誘導体 |
SE9904177D0 (sv) * | 1999-11-18 | 1999-11-18 | Astra Ab | Novel compounds |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
FR2812633A1 (fr) * | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
FR2815030A1 (fr) * | 2000-10-05 | 2002-04-12 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
JP2004517080A (ja) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Tie−2および/またはvegfr−2の阻害剤として有用なベンゾイミダゾール誘導体 |
ES2316486T3 (es) * | 2000-12-21 | 2009-04-16 | Schering Corporation | Antagonsitas de los receptores y5 del neuropeptido y heteroaril-urea. |
US6946476B2 (en) | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
KR100879669B1 (ko) * | 2001-04-27 | 2009-01-21 | 기린 파마 가부시끼가이샤 | 아졸릴기를 갖는 퀴놀린 유도체 및 퀴나졸린 유도체 |
JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
EP1395561A1 (de) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamat und oxamid verbindungen als inhibitoren der cytokinproduktion |
US6720321B2 (en) | 2001-06-05 | 2004-04-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
JP2004536845A (ja) | 2001-07-11 | 2004-12-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療方法 |
JP4825375B2 (ja) * | 2001-08-28 | 2011-11-30 | 株式会社 資生堂 | ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤 |
GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
EA007430B1 (ru) | 2001-09-26 | 2006-10-27 | Фармация Италия С.П.А. | Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция |
JP2005506350A (ja) | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
AU2003209118A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
WO2003068223A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
ES2299689T3 (es) | 2002-02-25 | 2008-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas. |
BR0311291A (pt) * | 2002-05-17 | 2005-03-29 | Pharmacia Italia Spa | Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
CN1678311A (zh) | 2002-06-27 | 2005-10-05 | 诺沃挪第克公司 | 用作治疗剂的芳基羰基衍生物 |
JP2005538066A (ja) | 2002-07-09 | 2005-12-15 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な抗コリン作用薬及びp38キナーゼ阻害剤を用いた新規な医薬組成物 |
JP2005538152A (ja) * | 2002-09-05 | 2005-12-15 | ニューロサーチ、アクティーゼルスカブ | ジアリール誘導体及びこれをクロライドチャネル遮断剤として使用する方法 |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
EP1615878B1 (de) * | 2003-01-14 | 2012-04-04 | Cytokinetics, Inc. | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
JP5229853B2 (ja) | 2003-02-28 | 2013-07-03 | ニッポネックス インコーポレイテッド | 癌その他の疾患の治療に有用な新規な二環尿素誘導体 |
CA2516627A1 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
MXPA05010496A (es) * | 2003-03-28 | 2005-11-16 | Pharmacia & Upjohn Co Llc | Moduladores alostericos positivos del receptor de acetilcolina nicotinico. |
JP2007511203A (ja) | 2003-05-20 | 2007-05-10 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害活性を有するジアリール尿素 |
DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
WO2005048953A2 (en) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
SI1723128T1 (sl) | 2004-01-06 | 2013-04-30 | Transtech Pharma, Inc. | Heteroaril uree in njihova uporaba kot aktivatorji glukokinaze |
EP1730111A2 (de) * | 2004-01-30 | 2006-12-13 | MERCK PATENT GmbH | Bisarylharnstoffderivate zur verwendung als kinase inhibitoren |
TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
EP1609789A1 (de) * | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazolderivate und ihre verwendung als kinaseinhibitoren |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2006062982A2 (en) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
CN104688697A (zh) | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
EP1925676A4 (de) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Testverfahren für die wirkung eines vaskularisierungsinhibitors |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
AU2006313701B2 (en) | 2005-11-11 | 2012-05-31 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
EP1959960B1 (de) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Bestimmte chemische entitäten, zusammensetzungen und verfahren |
US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
JP5178526B2 (ja) | 2005-12-19 | 2013-04-10 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
WO2007075650A2 (en) * | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
WO2007076460A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
MX2008014953A (es) | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
DE102006029795A1 (de) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | Neue Harnstoff-Derivate und deren Verwendungen |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
JP2010514692A (ja) | 2006-12-20 | 2010-05-06 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物 |
EP2119707B1 (de) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen |
WO2008125014A1 (fr) * | 2007-04-13 | 2008-10-23 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques |
AU2008242720A1 (en) | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
EP1992344A1 (de) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind |
CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
NZ591427A (en) | 2008-10-02 | 2012-12-21 | Respivert Ltd | P38 map kinase inhibitors |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
NZ593104A (en) | 2008-12-11 | 2012-11-30 | Respivert Ltd | P38 map kinase inhibitors |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
EP2467137A1 (de) * | 2009-08-19 | 2012-06-27 | Ambit Biosciences Corporation | Biarylverbindungen und anwendungsverfahren dafür |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
EP2508184A1 (de) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazinderivate und ihre Verwendungen |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
CN103172648B (zh) * | 2011-12-20 | 2016-05-25 | 上海迪诺医药科技有限公司 | 三杂环衍生物、制备方法及应用 |
US20150044178A1 (en) | 2011-12-28 | 2015-02-12 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
EP2890695A2 (de) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinaseinhibitoren |
UA117573C2 (uk) | 2012-11-13 | 2018-08-27 | Ерей Біофарма Інк. | Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю |
RS57001B1 (sr) | 2012-11-13 | 2018-05-31 | Array Biopharma Inc | Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kao inhibitori trka kinaze |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
AU2014219855B2 (en) * | 2013-02-19 | 2017-09-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
US9750723B2 (en) | 2013-10-31 | 2017-09-05 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
EP3069732B1 (de) | 2013-11-14 | 2023-07-12 | The Doshisha | Arzneimittel zur behandlung des hornhautendothels durch förderung der zellproliferation oder hemmung von zellschäden |
HUE045340T2 (hu) | 2014-05-15 | 2019-12-30 | Array Biopharma Inc | 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor |
US20170202818A1 (en) | 2014-07-18 | 2017-07-20 | Ohio University | Methods and compositions to modify gsk-3 activity |
EP3180335B1 (de) | 2014-08-11 | 2021-05-05 | Angion Biomedica Corporation | Zytochrom-p450-hemmer und verwendungen davon |
RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
SG11201701694QA (en) | 2014-09-10 | 2017-04-27 | Glaxosmithkline Ip Dev Ltd | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
CR20170094A (es) | 2014-09-10 | 2017-05-08 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) |
US9638690B2 (en) | 2014-11-07 | 2017-05-02 | The University Of British Columbia | Compounds and compositions for use as alkylating agent sensors and methods of use thereof |
CA2970819A1 (en) | 2014-12-31 | 2016-07-07 | Angion Biomedica Corp. | Methods and agents for treating disease |
PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
AU2020329956B2 (en) | 2019-08-12 | 2023-11-16 | Deciphera Pharmaceuticals, Llc. | Ripretinib for treating gastrointestinal stromal tumors |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
BR112022013109A2 (pt) | 2019-12-30 | 2022-09-06 | Deciphera Pharmaceuticals Llc | Formulações de inibidor de quinase amorfo e métodos de uso das mesmas |
JP2023509628A (ja) | 2019-12-30 | 2023-03-09 | デシフェラ・ファーマシューティカルズ,エルエルシー | 1-(4-ブロモ-5-(1-エチル-7-(メチルアミノ)-2-オキソ-1,2-ジヒドロ-1,6-ナフチリジン-3-イル)-2-フルオロフェニル)-3-フェニル尿素の組成物 |
CN116102522A (zh) * | 2021-11-09 | 2023-05-12 | 河南省化工研究所有限责任公司 | 一种阳离子蓝染料中间体的制备方法 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3646059A (en) * | 1969-05-05 | 1972-02-29 | Du Pont | Plant growth regulatory ureidopyrazoles |
JP3108097B2 (ja) * | 1991-01-21 | 2000-11-13 | 塩野義製薬株式会社 | 3−ベンジリデン−1−カルバモイル−2−ピロリドン類縁体 |
US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
ATE186551T1 (de) | 1993-09-17 | 1999-11-15 | Smithkline Beecham Corp | Medikamente bindendes protein |
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US5932576A (en) * | 1997-05-22 | 1999-08-03 | G. D. Searle & Company | 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
US6087381A (en) * | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
EP1019040B1 (de) * | 1997-05-23 | 2004-09-29 | Bayer Corporation | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
AU7966198A (en) * | 1997-06-13 | 1998-12-30 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
AU1367599A (en) * | 1997-11-03 | 1999-05-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
ES2155045T3 (es) * | 1997-12-22 | 2007-02-01 | Bayer Pharmaceuticals Corp. | Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. |
ES2155817T3 (es) * | 1997-12-22 | 2007-06-16 | Bayer Pharmaceuticals Corp. | Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. |
JP4437270B2 (ja) * | 1997-12-22 | 2010-03-24 | バイエル コーポレイション | 置換複素環式尿素を用いたrafキナーゼの阻害 |
-
1998
- 1998-12-22 JP JP2000525102A patent/JP4403482B2/ja not_active Expired - Fee Related
- 1998-12-22 EP EP98964709A patent/EP1041982B1/de not_active Expired - Lifetime
- 1998-12-22 IL IL13673898A patent/IL136738A0/xx active IP Right Grant
- 1998-12-22 ES ES98964709T patent/ES2154253T3/es not_active Expired - Lifetime
- 1998-12-22 AT AT98964709T patent/ATE529109T1/de not_active IP Right Cessation
- 1998-12-22 WO PCT/US1998/026080 patent/WO1999032111A1/en active Application Filing
- 1998-12-22 AU AU19971/99A patent/AU739642B2/en not_active Ceased
- 1998-12-22 CA CA002315720A patent/CA2315720A1/en not_active Abandoned
- 1998-12-22 DE DE1041982T patent/DE1041982T1/de active Pending
- 1998-12-22 MX MXPA00006233A patent/MXPA00006233A/es not_active Application Discontinuation
-
2000
- 2000-06-12 IL IL136738A patent/IL136738A/en not_active IP Right Cessation
-
2005
- 2005-08-10 IL IL170201A patent/IL170201A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU739642B2 (en) | 2001-10-18 |
JP4403482B2 (ja) | 2010-01-27 |
EP1041982A1 (de) | 2000-10-11 |
EP1041982A4 (de) | 2006-06-14 |
IL136738A (en) | 2007-06-17 |
WO1999032111A1 (en) | 1999-07-01 |
ES2154253T1 (es) | 2001-04-01 |
IL170201A (en) | 2006-12-31 |
IL136738A0 (en) | 2001-06-14 |
AU1997199A (en) | 1999-07-12 |
MXPA00006233A (es) | 2002-09-18 |
ES2154253T3 (es) | 2012-01-27 |
JP2001526223A (ja) | 2001-12-18 |
CA2315720A1 (en) | 1999-07-01 |
DE1041982T1 (de) | 2001-06-07 |
EP1041982B1 (de) | 2011-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE529109T1 (de) | Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe | |
DE1019040T1 (de) | Hemmung von p38 kinase aktivität durch arylharnstoff | |
ATE346600T1 (de) | Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen | |
PT1042305E (pt) | Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas | |
ATE556713T1 (de) | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer | |
BR9811956B1 (pt) | naftiridinonas e composição farmacêutica compreendendo as mesmas. | |
TR200100918T2 (tr) | Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi | |
ATE296799T1 (de) | P38-inhibitoren | |
ID26956A (id) | Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea | |
JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
PT966465E (pt) | Inibidores do enzima imfdh | |
ATE458724T1 (de) | N-heterocyclische inhibitoren der expression von tnf-alpha | |
BG105763A (en) | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |